The highly anticipated Alzheimer’s drug lecanemab was granted accelerated approval status this afternoon by the FDA, offering hope where there has been little for patients and their families affected by the devastating disease. More than 6 million people in the U.S. live with Alzheimer’s. It’s not a cure, but the drug, given intravenously every 2 weeks,...Read More